Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMR) in the company's Ordinary shares, specifically regarding the vesting of awards under the GlaxoSmithKline Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of executive share transactions rather than a financial performance report.
Material Changes
The material change reported is the vesting of 50% of awards made under the Deferred Investment Award Plan on September 18, 2011. Specific transactions include:
- Ms C Thomas: Vesting of 5,850.558 Ordinary shares.
- Mr D Redfern: Vesting of 9,360.893 Ordinary shares.
Both individuals are scheduled to receive a payment of 1302.50 pence per Ordinary share on October 20, 2011.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share vesting events in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the payment date of October 20, 2011, for the vested shares.
- Confirm the share price of 1302.50 pence per Ordinary share at the time of payment.
- Review the total number of vested shares for Ms C Thomas (5,850.558) and Mr D Redfern (9,360.893).